1. A simple point-of-care assay accurately detects anti-spike antibodies after SARS-CoV-2 vaccination
- Author
-
Greene, Sarah E, Huang, Yuefang, Kim, Wooseob, Liebeskind, Mariel J, Chandrasekaran, Vinay, Liu, Zhuoming, Deepak, Parakkal, Paley, Michael A, Lew, Daphne, Yang, Monica, Matloubian, Mehrdad, Gensler, Lianne S, Nakamura, Mary C, O'Hallaran, Jane A, Presti, Rachel M, Whelan, Sean PJ, Buchser, William J, Kim, Alfred HJ, and Weil, Gary J
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Vaccine Related ,Emerging Infectious Diseases ,Biodefense ,Biotechnology ,Infectious Diseases ,Clinical Research ,Immunization ,Prevention ,Infection ,Good Health and Well Being ,SARS-COV-2 ,Antibody test ,Vaccination ,Immunocompromise - Abstract
ObjectiveLateral flow assays (LFA) are sensitive for detecting antibodies to SARS-CoV-2 proteins within weeks after infection. This study tested samples from immunocompetent adults, and those receiving treatments for chronic inflammatory diseases (CID), before and after mRNA SARS-CoV-2 vaccination.MethodsWe compared results obtained with the COVIBLOCK Covid-19 LFA to those obtained by anti-spike (S) ELISA.ResultsThe LFA detected anti-S antibodies in 29 of 29 (100%) of the immunocompetent and 110 of 126 (87.3%) of the CID participants after vaccination. Semiquantitative LFA scores were statistically significantly lower in samples from immunosuppressed participants, and were significantly correlated with anti-S antibody levels measured by ELISA.ConclusionsThis simple LFA test is a practical alternative to laboratory-based assays for detecting anti-S antibodies after infection or vaccination. This type of test may be most useful for testing people in outpatient or resource-limited settings.
- Published
- 2023